Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ACST CVE:KNE CVE:LTY TSE:REUN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti PharmaC$0.58+1.8%C$0.58C$0.47▼C$1.66C$18.19M1.226,576 shs2,450 shsKNEKane BiotechC$0.03C$0.03C$0.03▼C$0.07C$6.15M0.973941192,896 shs11,000 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsREUNReunion NeuroscienceC$0.00C$0.83▼C$6.56C$16.64M4.212,447 shs339 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%0.00%KNEKane Biotech0.00%0.00%-14.29%-14.29%-50.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti PharmaC$0.58+1.8%C$0.58C$0.47▼C$1.66C$18.19M1.226,576 shs2,450 shsKNEKane BiotechC$0.03C$0.03C$0.03▼C$0.07C$6.15M0.973941192,896 shs11,000 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsREUNReunion NeuroscienceC$0.00C$0.83▼C$6.56C$16.64M4.212,447 shs339 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%0.00%KNEKane Biotech0.00%0.00%-14.29%-14.29%-50.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 0.00N/AN/AN/AKNEKane Biotech 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/AREUNReunion Neuroscience 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaC$2.71M6.71C$0.93 per share0.63C$1.56 per share0.37KNEKane BiotechC$58.57K105.02C$0.00 per share8.50C($0.01) per share-3.85LTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/AREUNReunion NeuroscienceC$4.86M0.00N/AN/AC$1.82 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-C$10.54M-C$0.48N/AN/AN/A-455.58%-67.58%-8.25%N/AKNEKane BiotechC$6.03M-C$0.01N/AN/AN/A-3,785.93%277.77%-58.43%N/ALTYLiberty BiopharmaN/A-C$0.16N/AN/AN/AN/AN/AN/AN/AREUNReunion Neuroscience-C$38.10M-C$3.30N/AN/AN/AN/A-86.35%-26.50%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AKNEKane BiotechN/A3.08%N/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AREUNReunion NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A4.139.41KNEKane Biotech-135.170.450.39LTYLiberty Biopharma8.190.120.12REUNReunion NeuroscienceN/A3.52N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma0.11%KNEKane Biotech0.65%LTYLiberty BiopharmaN/AREUNReunion Neuroscience50.66%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma20.28%KNEKane Biotech37.21%LTYLiberty BiopharmaN/AREUNReunion Neuroscience34.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma3231.37 millionN/ANot OptionableKNEKane BiotechN/A205.06 millionN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableREUNReunion Neuroscience19011.72 millionN/ANot OptionableKNE, LTY, ACST, and REUN HeadlinesRecent News About These CompaniesReunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEOJune 15 at 8:27 AM | finance.yahoo.comReunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ...May 12, 2026 | caledonianrecord.comCReunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual MeetingsMay 11, 2026 | globenewswire.comLuvesilocin Designated Breakthrough Therapy for Postpartum DepressionFebruary 23, 2026 | empr.comEU.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation StatusFebruary 23, 2026 | markets.businessinsider.comReunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual MeetingJanuary 20, 2026 | markets.businessinsider.comReunion Neuroscience expands Series A to $133m after positive trial milestonesSeptember 16, 2025 | finance.yahoo.comAbbVie wagers more than $1B on Gilgamesh’s psychedelic drugAugust 25, 2025 | biopharmadive.comBReunion’s psychedelic prodrug reduces postpartum depression symptoms in ph. 2 studyAugust 18, 2025 | fiercebiotech.comFSome postpartum moms are using psychedelics — experts say they may be onto somethingAugust 1, 2025 | msn.comReAlta Life Sciences Names Ellen Lubman as Chief Business OfficerJuly 28, 2025 | contractpharma.comCReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business OfficerJuly 28, 2025 | finance.yahoo.comPsychedelics may improve psychotherapy outcomes, but obstacles remainJuly 3, 2025 | healio.comHShares of psychedelics biotech nearly double on depression dataFebruary 3, 2025 | biopharmadive.comB5 More Things We Learned from the "Love Is Blind" ReunionNovember 10, 2024 | psychologytoday.comPRx Rundown: AstraZeneca, Danco Laboratories, GSK and moreOctober 11, 2024 | mmm-online.comMOasis Bringing 2025 Reunion Tour To North AmericaSeptember 30, 2024 | spin.comSWhy are so many Roman statues headless?August 26, 2024 | msn.comTopics in Integrative NeuroscienceAugust 23, 2024 | cambridge.orgCCT’s younger generations are really worried about climate change. They’re doing something about it.August 12, 2024 | courant.comCMedia Sentiment Over Time Top HeadlinesView All HeadlinesEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthBy Leo Miller | June 10, 2026Deere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookBy Chris Markoch | May 22, 20263 Multi-Metal Stocks for Income and Long-Term GrowthBy Chris Markoch | June 8, 20263 Ways to Play the Data Center Land GrabBy Nathan Reiff | May 31, 2026Palomar’s High-Risk Insurance Strategy Is Paying Off BigBy Peter Frank | May 29, 2026KNE, LTY, ACST, and REUN Company DescriptionsAcasti Pharma CVE:ACSTC$0.58 +0.01 (+1.75%) As of 03/27/2023Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.Kane Biotech CVE:KNEC$0.03 0.00 (0.00%) As of 04:02 PM EasternKane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Reunion Neuroscience TSE:REUNReunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
